What happens to clinical skills when AI does the routine work?
-
By
-
Doug Brunk
-
September 1, 2026
-
7 min
By
Doug Brunk
September 1, 2026
The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.
July 8, 2026
Patients with blood type O showed a stronger reaction signal in US regions with high alpha-gal syndrome prevalence.
August 27, 2026
An ancillary analysis found less than 2-percentage-point differences in 10-year recurrence across margin thresholds, with no statistically significant adjusted association.
July 20, 2026